When will the patents on ETRAFON 2-10 expire, and when will ETRAFON 2-10 go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	ETRAFON 2-10	amitriptyline hydrochloride; perphenazine	TABLET;ORAL	014713-007	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

ETRAFON 2-10, a fixed-dose combination of amitriptyline and perphenazine, presents a complex investment scenario driven by its established therapeutic profile and an evolving patent and market landscape. The drug is indicated for the treatment of moderate to severe depression and anxiety. Its market presence is characterized by generic competition, but opportunities may exist in specific market segments or through lifecycle management strategies.

What Is the Current Market Status of ETRAFON 2-10?

ETRAFON 2-10 is an older pharmaceutical product, first approved by the U.S. Food and Drug Administration (FDA) in 1963. It is a combination of amitriptyline, a tricyclic antidepressant (TCA), and perphenazine, a typical antipsychotic.

Therapeutic Indications: Primarily used for patients suffering from moderate to severe depression with associated anxiety.
Market Presence: The brand name ETRAFON has a long history, but the market is now dominated by generic versions of amitriptyline and perphenazine, both as individual agents and in combination products.
Sales Data: Specific, up-to-date global sales figures for the branded ETRAFON 2-10 are not readily available in public domain financial reports, as it is likely a mature product with sales figures aggregated within broader generic product lines or older company portfolios. However, the overall market for antidepressants and antipsychotics remains substantial. The global antidepressant market was valued at approximately USD 20 billion in 2023, with the antipsychotic market exceeding USD 25 billion in the same year [1]. The specific market share attributable to fixed-dose combination products like ETRAFON 2-10 is a subset of these broader markets.
Competitive Landscape: ETRAFON 2-10 competes with a wide array of newer antidepressants, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antipsychotics. These newer agents often have more favorable side effect profiles and are perceived as more advanced treatments, leading to a significant shift in prescribing patterns away from older TCAs and typical antipsychotics.

What Is the Patent Protection Status for ETRAFON 2-10?

The original patents protecting ETRAFON 2-10 have long expired. As a drug first approved in the mid-20th century, its composition-of-matter patents would have lapsed decades ago.

Original Composition Patents: Expired. The fundamental patent protection for the chemical entities of amitriptyline and perphenazine, and their initial combination formulation, has concluded.
Potential for New Patents: While original composition patents are expired, pharmaceutical companies may seek to extend market exclusivity through new patents related to:
- New Formulations: Development of extended-release formulations, novel delivery systems, or improved solid-state forms (polymorphs).
- New Indications: Discovery of new therapeutic uses for the existing combination.
- Manufacturing Processes: Novel, more efficient, or environmentally friendly synthesis routes.
- Combination Therapies: Use of ETRAFON 2-10 in conjunction with other specific agents for synergistic effects.
Generic Entry: The lack of active patent protection for the original product has facilitated widespread generic entry, leading to significant price erosion and market fragmentation. Generic manufacturers can produce and market bioequivalent versions of ETRAFON 2-10 once branded exclusivity has expired.
Exclusivity Periods: The Hatch-Waxman Act in the U.S. provides certain periods of market exclusivity for new drug applications (NDAs) and for the first generic approval. However, for a drug approved in 1963, these provisions are not applicable to the original formulation. Exclusivity might have been relevant if a new formulation or indication was approved more recently and sought 505(b)(2) or 505(j) pathways.

What Are the Key Risks Associated with Investing in ETRAFON 2-10?

Investing in a mature product like ETRAFON 2-10 carries inherent risks primarily related to market dynamics, competition, and regulatory considerations.

Generic Competition and Price Erosion: This is the most significant risk. The market is flooded with generic alternatives for both amitriptyline and perphenazine, driving down prices and reducing profit margins for any remaining branded product.
Declining Prescribing Trends: Newer antidepressant and antipsychotic medications with improved safety profiles and efficacy in specific patient populations have largely replaced older TCAs and typical antipsychotics. This shift in physician preference leads to a steady decline in the demand for ETRAFON 2-10.
Side Effect Profile: Amitriptyline is associated with anticholinergic side effects (dry mouth, constipation, urinary retention), cardiovascular effects (orthostatic hypotension, arrhythmias), and sedation. Perphenazine can cause extrapyramidal symptoms (EPS) such as akathisia, dystonia, and parkinsonism, as well as tardive dyskinesia with long-term use. These side effect profiles are a major deterrent compared to newer agents.
Limited Innovation Potential: The core drug substance and its basic formulation are well-established. Significant innovation or pipeline development based on ETRAFON 2-10 is unlikely due to its age and the availability of more targeted therapies.
Regulatory Scrutiny: As with all medications, ETRAFON 2-10 is subject to ongoing regulatory oversight. Changes in prescribing guidelines, post-market safety surveillance, or new labeling requirements can impact its marketability.
Market Obsolescence: The drug may eventually be considered obsolete by many healthcare providers and payers as more effective and safer alternatives become standard of care.

What Are Potential Opportunities or Strategic Considerations for ETRAFON 2-10?

Despite the significant risks, limited opportunities might exist, often requiring specific market positioning or niche strategies.

Cost-Effectiveness in Specific Markets: In healthcare systems with strict cost controls or in regions where access to newer, more expensive medications is limited, ETRAFON 2-10 could remain a viable, cost-effective option for depression and anxiety management.
Specific Patient Populations: While less common, certain patient profiles might still benefit from the amitriptyline-perphenazine combination, particularly if they have not responded to newer agents or have specific co-morbidities where the combination's profile is managed. This would require targeted marketing and physician education, which is challenging for a genericized product.
Geographic Niches: Some emerging markets might have a slower adoption rate of newer psychopharmacological agents, potentially extending the lifespan of older fixed-dose combinations.
Supply Chain Control: For a generic manufacturer, securing reliable and low-cost manufacturing for both active pharmaceutical ingredients (APIs) and finished dosage forms would be critical to remaining competitive in this price-sensitive market.
Lifecycle Management (Limited Scope): If a company held rights to a specific formulation or a very recent patent (e.g., on a novel manufacturing process or polymorph), there might be a limited window for maintaining some market position. However, given the drug's history, this is improbable for the core product.

What Are the Financial and Economic Factors for ETRAFON 2-10?

The financial outlook for ETRAFON 2-10 is predominantly shaped by its status as a legacy product facing intense generic competition.

Revenue Streams: Primarily derived from sales of generic amitriptyline-perphenazine combination products. Revenue for any remaining branded ETRAFON 2-10 would be minimal and declining.
Profit Margins: Generally low due to price pressure from generics. Generic manufacturers focus on volume and efficient production to maintain profitability.
Manufacturing Costs: Costs are relatively stable for well-established generic products. Economies of scale in production are crucial. The APIs (amitriptyline HCl and perphenazine) are widely available from multiple suppliers.
R&D Investment: Negligible for the original product. Any investment would be related to maintaining manufacturing quality, regulatory compliance, or potentially very minor formulation adjustments to distinguish a generic product (e.g., scoring for easier division).
Market Valuation: The market valuation of any company with significant ETRAFON 2-10 generic sales would be influenced by its broader generic portfolio and manufacturing capabilities, rather than the specific contribution of this single legacy product.
Reimbursement Landscape: Reimbursement for generic combination products is typically at their average wholesale price (AWP) or negotiated rates, which are considerably lower than for branded or newer drugs. Payer formularies may favor newer agents, further limiting ETRAFON 2-10's access.

What Are the Regulatory and Compliance Requirements?

Regulatory compliance for ETRAFON 2-10, particularly in the U.S., involves adherence to FDA standards for generic drugs.

Abbreviated New Drug Applications (ANDAs): Generic versions are approved via ANDAs, requiring demonstration of bioequivalence to the reference listed drug (RLD).
Good Manufacturing Practices (GMPs): Manufacturers must adhere to strict GMP regulations to ensure product quality, safety, and efficacy. This includes facility inspections, process validation, and quality control.
Labeling Requirements: Generic drug labeling must be identical to the RLD's labeling, except for minor differences in inactive ingredients or expiration dates, and must include a National Drug Code (NDC) number.
Pharmacovigilance: Ongoing monitoring of adverse events and reporting to regulatory authorities is mandatory.
Post-Approval Changes: Any changes to manufacturing processes, sites, or formulation require FDA approval.
International Regulations: Compliance with the regulatory bodies of other countries (e.g., EMA in Europe, PMDA in Japan) is necessary for international sales.

Key Takeaways

ETRAFON 2-10 represents a legacy pharmaceutical product facing significant market headwinds. Its investment profile is characterized by:

Market Maturity: The drug is a mature product with original composition patents long expired, leading to pervasive generic competition.
Price Erosion: Intense genericization has driven down prices and profit margins.
Declining Prescribing: Newer psychotropic medications with superior safety and efficacy profiles have largely superseded ETRAFON 2-10.
Limited Innovation: The potential for significant pipeline development or lifecycle management is negligible.
Niche Survival: Any remaining market presence is likely confined to cost-sensitive markets or specific patient subsets, requiring efficient generic manufacturing and supply chain management.

Frequently Asked Questions

What is the primary therapeutic use of ETRAFON 2-10? ETRAFON 2-10 is used for the treatment of moderate to severe depression accompanied by anxiety.
Has the patent protection for ETRAFON 2-10 expired? Yes, the original patents covering the composition of matter and initial formulations of amitriptyline and perphenazine, and their combination as ETRAFON 2-10, expired decades ago.
What is the main risk associated with investing in ETRAFON 2-10? The primary risk is intense generic competition and consequent price erosion, coupled with declining physician preference for older drug classes.
Are there any current opportunities for ETRAFON 2-10? Limited opportunities may exist in cost-sensitive healthcare systems or specific geographic markets where newer, more expensive treatments are less accessible, or for generic manufacturers with highly efficient production capabilities.
What regulatory pathway is used for generic versions of ETRAFON 2-10? Generic versions are approved by the U.S. Food and Drug Administration through the Abbreviated New Drug Application (ANDA) process, requiring demonstration of bioequivalence to the reference listed drug.

Citations

[1] Grand View Research. (2023). Antidepressant Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/antidepressant-market [2] Grand View Research. (2023). Antipsychotic Drugs Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/antipsychotic-drugs-market

ETRAFON 2-10 Drug Patent Profile

Which patents cover Etrafon 2-10, and when can generic versions of Etrafon 2-10 launch?

AI Deep Research

Questions you can ask:

Summary for ETRAFON 2-10

US Patents and Regulatory Information for ETRAFON 2-10

ETRAFON 2-10: Investment Fundamentals and Patent Landscape